TWO TYPES OF SYSTEMIC AMYLOIDOSIS IN A SINGLE PATIENT

Riccardo Papa1, Janet A. Gilbertson2, Nigel Rendell2, Ashutosh Wechalekar2, Julian D. Gillmore2, Philip N. Hawkins2, Helen J. Lachmann2.

1IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; 2Amyloidosis Centre, London, United Kingdom

Objective: To describe the history of two types of amyloidosis in the same patient diagnosed consecutively in a single individual.

Methods: Targeted biopsies were used to confirm the presence of amyloid by Congo red staining viewed under polarized light, while immunohistochemistry and mass spectrometry were used to characterize the amyloid fibril type. 11C labeled serum amyloid P component (SAP) scintigraphy was performed to map the distribution of amyloid deposits.

Results: We report a woman of Sudanese origin who presented aged 31 with amyloidosis. I123-labeled serum amyloid P component (SAP) scintigraphy was used to confirm the presence of amyloidosis. Targeted biopsies were used to confirm the presence of amyloid by Congo red staining viewed under polarized light, while immunohistochemistry and mass spectrometry were used to characterize the amyloid fibril type. 11C labeled serum amyloid P component (SAP) scintigraphy was performed to map the distribution of amyloid deposits.

Conclusion: Despite of being a well-known condition, VO is still an issue since 1-2 out 10 patients have a serious complication at diagnosis, such as AP. None of the basal characteristics analyzed acted as a risk factor, though AP group showed more proportion of prior spine pathology. No delay in diagnosis was noted on AP patients, but higher CRP value at diagnosis has been observed and predilection towards dorsal spine. Almost all patients tend to improve their ASIA scale, but in every case, some physical damage remain. More than a half required surgical procedure after diagnosis and mortality seems to be higher in this group.

REFERENCE

Disclosure of Interests: None declared

RHEUMATIC LYME DISEASE SYMPTOMS BASED ON EPIDEMIOLOGICAL DATA IN HIGH ENDEMIC AREA

Agne Petulionienė1, Daiva Radvilsai1enė2, Anydas Ambrozaitis2, Saulius Čaplinskas3,4, Algimantas Paulauskas5, Algirdas Venalis1,6, 1Clinic of Rheumatology, Orthopaedics Traumatology and Reconstructive Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 2Center for Communicable Diseases and AIDS, Vilnius, Lithuania; 3Mykolas Romeris University, Vilnius, Lithuania; 4Vytautas Magnus University, Kaunas, Lithuania; 5State research Institute Center for Innovative Medicine, Vilnius, Lithuania

Background: Lyme disease is a tick born infectious disease caused by different genospecies of Borrelia bacteria (B. burgdorferi sensu strictu (ss), B. afzelii and B. garinii). The signs and symptoms of Lyme disease vary, they usually appear in stages, but the stages can overlap. Early stage skin rash (erythema migrans) appears, which may be accompanied by fever, chills, fatigue, body aches, headache, neck stiffness, and swollen lymph nodes. Later signs and symptoms can be these: joint pain and inflammation, neurological problems or other less common syndromes - heart problems, eye inflammation, and liver inflammation. Lyme disease is very common disease in the world, approximately 300,000 people get Lyme disease each year in the United States (Centers for disease control and prevention US), in Lithuania disease frequency is 101.6 cases per 100 000 population (Center for Communicable Diseases and AIDS, Lithuania, 2016 year).

Objectives: To investigate the frequency of rheumatic symptoms between Lyme diagnosed persons in Lithuania, based on epidemiological data.

REFERENCES

Acknowledgement: The presenting author would like to thank the European Federation of Immunology (EFIS) for the short-term fellowship bursary

Disclosure of Interests: Riccardo Papa: None declared, Janet A. Gilbertson: None declared, Nigel Rendell: None declared, Ashutosh Wechalekar: None declared, Julian D. Gillmore: None declared, Philip N Hawkins: None declared, Helen J. Lachmann: Grant/research support from: SOBI, Novartis, Consultant for: Novartis, Takeda, Speakers bureau: SOBI, Novartis
Methods: We have analyzed data of Center for Communicable Diseases and AIDS of Lithuania about Lyme diagnosed patients from 2014 to 2016 years.

Results: Total number of cases was 7425, 2791 males, 4633 females, age range 1 - 91 years, median age 52 years. 996 patients found out as symptomatic. The rest were either asymptomatic either information about clinical disease manifestation was not known. Among symptomatic patients two rheumatic symptoms were observed: arthralgia (220 cases, 22.1%), 140 females, 80 males, age range 12 – 84 years, median age 58 years, and myalgia (79 cases, 7.8%), 44 females, 34 males, age range 15-80, median age 56. Other symptoms were erythema migrans (75.6%), headache (15.2%), general weakness (12.4%), fever (10, 1%), and head dizziness (6.4%).

Conclusion: In total, almost 30 percentages (29, 91%) of symptoms were rheumatic. To conclude, joint pain and/or muscle pain can lead not only to systemic rheumatic diseases, but to infection diseases as well (for example: Lyme disease).

REFERENCES

Disclosure of Interests: None declared

AB0903
LYME ARTHRITIS IN HIGH LYME DISEASE ENDEMIC EUROPE ZONE

Agnė Petruniūnienė1, Daiva Radžiauskienė2, Anvydas Ambrozaitis3, Saulius Čaplikšnienė4,5, Algimantas Paulauskas6, Algirdas Venaliūnas5,6. 1Clinic of Rheumatology, Orthopaedics Traumatology and Reconstructive Surgery, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania; 2Center for Communicable Diseases and AIDS, Vilnius, Lithuania; 3Mykolas Romeris University, Vilnius, Lithuania; 4Vytanaitė Magnus University, Kaunas, Lithuania; 5State research Institute Center for Innovative Medicine, Vilnius, Lithuania

Background: Lyme disease is a tick born infectious disease caused by different genospecies of Borrelia bacteria (B. burgdorferi sensu strictu, B. afzelii and B. garinii). Disease clinical manifestation varies and belong on the variety of Borrelia bacteria genospecies. In America Lyme arthritis dominates, which is caused by B.burgdorferi, while in Europe Lyme disease is caused by Borrelia afzelii or Borrelia garinii (less commonly by Borrelia burgdorferi) leading to usual disease manifestation as erythema migrans or neuroborreliosis. Lyme disease is very common disease in the world, approximately 300,000 people get Lyme disease each year in the United States (Centers for disease control and prevention US), in Lithuania disease frequency is 101.6 cases per 100 000 population (Cen- ter for Communicable Diseases and AIDS, Lithuania, 2016 year).

Objectives: To investigate the frequency of Lyme arthritis in high disease endemic European country Lithuania. To find out with joint was most fre- quently affected.

Methods: A retrospective, single center study was performed. We have analyzed the medical documents of adult patients, who were hospitalized to Infectious disease center (Vilnius, Lithuania), due to severe Lyme dis- ease clinical manifestation, in 2014-2017 years.

Results: 88 patients were enrolled (57 females, 31 males, age range 18- 90 years, median age 57 years). Patients were divided into four groups according disease clinical manifestation: erythema migrans, neuroborrelio- sis, Lyme arthritis and carditis (atrioventricular block). The most frequently erythema migrans was observed (53 cases, 62, 35 percentages (%)), than neuroborreliosis (27 cases, 31, 76 percentages), following by Lyme arthritis (3 cases, 3, 53 percentages) and Lyme carditis (2 cases, 2, 35 percentages). Between Lyme arthritis patients inflamed joints were these: knee (one case), ankle (one case) and both - knee and ankle (one case). In two cases, high laboratory markers (ESR 116, 23 mm/min, CRP 125, 50 mg/l) and high body temperature (38, 2; 39, 5 0 t) was documented.

Conclusion: 2.35% of hospitalized Lyme infected patients reveal as Lyme arthritis. Inflamed joint were knee (50%) and ankle (50%). Despite the fact that it is used to think that Lyme arthritis occurs only (mostly) in America we can find it in Europe too, though its incidence is low.

REFERENCES

Disclosure of Interests: None declared

AB0904
EFFECTIVENESS AND SAFETY OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES: A CASE SERIES DESCRIBING THE EXPERIENCE OF AN AUTOIMMUNE DISEASES UNIT IN A 3-YEAR PERIOD

Milagros Suárez, Ana Argibay, Clara Portela, Olalla Lima, Lorena María Rodríguez Ferreira, Melanía Estevez, Brenda Maure, Carinta Vázquez Trifán, Beatriz Gimena, Rut Lorenzo, Julian Fernandez, Alberto Rivera, Systemic Autoimmune diseases and Thrombosis Unit, University Hospital of Vigo, Spain; Hospital Álvaro Cunqueiro, Vigo, Spain

Background: Rituximab (RTX) is a drug composed of chimeric monoclo- nal antibodies against the CD20 protein, producing a depletion of B lymphocytes. Nowadays, it is used to treat severe and refractory systemic autoimmune diseases (SAD).

Objectives: Analysing the effectiveness and safety of RTX in patients with SAD in clinical practice.

Methods: We conducted a retrospective analysis of patients with SAD treated at least once with RTX in the autoimmune diseases unit of our hospital in the last 3 years. We evaluated demographic, clinical and soro- logical variables as well as the presence of adverse events (AE).

Results: Twenty two patients have been included (13 women and 9 men, mean age 63 ±15 years). The diagnosis were ANCA-associated vasculitis (31.8%), cryoglobulinemic vasculitis (18.2%), autoimmune hemo- lytic anemia (13.6%), systemic lupus erythematosus (9.1%), immune thrombocytopenia in antiphospholipid syndrome (9.1%) and one each of: Felty syndrome, IgG4-related disease, necrotizing myopathy and systemic sclerosis. Indications for treatment were renal disease in 36.4% of the cases, haematological manifestations in 27.3%, skin involvement in 13.6%, neurologic manifestations in 9.1% and other different reasons in the remaining 15.6%. RTX was used after therapeutic failure with pre- vious treatments in 81.8% and as first line treatment in only 18.1% of the cases. RTX dose was 375 mg/m² once weekly for 4 doses (54,5%) and 1000 mg on days 1 and 15 (45,5%). After rituximab, 77,3% of patients had complete response, 9,1% partial response, and 13,7% non- responding. There were 14 AE reported in 10 of the 22 patients (45,5%) (See table). Three severe infections were found: 2 patients with invasive pulmonary aspergillosis and 1 patient with invasive cryptococco- sis. All of them died within the next month after beginning RTX. One of those who were diagnosed of argeplasias had never received steroids. The other two were treated with high dose of steroids for several months. One patient had a nonischemic cardiomyopathy (NIC) with sys- tolic dysfunction that resolved 4 months after RTX discontinuation.

Conclusion: As far as we are concern, RTX is a useful and pretty safe biological agent in the treatment of refractory SAD. However, we must be aware of rare adverse effects such as NIC. In addition, given the poten- tial severity of the infections found (although not totally attributable to RTX), we must closely follow up these patients for early diagnosis, treat- ment and even starting profilaxis in high risk patients.